HOME >> BIOLOGY >> NEWS
Understanding the life of C. elegans

HOUSTON (April 4, 2006) When the nematode Caenorhabditis elegans has enough to eat, enjoys the right temperatures and is not crowded out by its fellows, it produces a hormone, which binds to a receptor called DAF12 that allows it to reach reproductive maturity and live a natural lifespan.

When conditions are harsher, however, the worm a classic model organism frequently studied in the laboratory does not produce the hormone and enters a special stage called the dauer diapause in which it remains an immature larva until the situation improves. In a paper that appears in the journal Developmental Cell, Baylor College of Medicine researchers led by Dr. Adam Antebi, assistant professor in the BCM Huffington Center on Aging and the department of molecular and cellular biology, identify a new gene called DAF-36 involved in making this hormone.

"Our evidence suggests that DAF-36 works early in a pathway that converts cholesterol through a series of enzymatic steps into the dafachronic acids, the active ligands for DAF-12 nuclear receptor," said Antebi. In this instance, a ligand is a molecule that binds to a specific site on a protein.

These particular ligands promote the maturation of the C. elegans reproductive capacity and prevent the organism from going into the immature long-lived larval phase called dauer diapause. Antebi and collaborators identified these ligands in a report that appeared March 24, 2006 in the journal Cell.

In addition, said Antebi, DAF-36 is required for the long life seen in forms of C. elegans that lack germline cells those cells like sperm and egg in animals are necessary for reproduction.

In a related work published in Cell (Motola et al. 2006), the chemical identification of the DAF-12 ligands as steroid-like hormones is reported, providing the first evidence for steroid control of maturation in worms. Antebi speculates that this may resemble how estrogen and androgen hormones similarly gover
'"/>

Contact: Kimberlee Barbour
kbarbour@bcm.edu
713-798-4712
Baylor College of Medicine
4-Apr-2006


Page: 1 2

Related biology news :

1. Understanding why C. difficile causes disease -- its hungry
2. Understanding the global carbon budget -- Woods Hole Research Center expert provides insights
3. Understanding occupational safety and health issues of nanotechnology
4. Understanding the Arctic -- NSF-funded expeditions cover new ground in climate science
5. Understanding climate change: Public forum in Philadelphia next week
6. Understanding food nutrition labels challenging for many people
7. Understanding of cell protection mechanism points to therapies to prevent heart attacks and strokes
8. Drawing a crowd: Understanding the signals that bring inflammatory cells into the lung
9. Jane Lubchenco receives the 2005 AAAS Public Understanding of Science and Technology Award
10. Understanding the oceans microbes is key to the Earths future
11. Understanding IGF-1: Jefferson researcher sees drug potential in targeting enzyme

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Understanding the life elegans

(Date:3/11/2015)... , March 11, 2015   The ... its platform to scientifically measure and harness music ... to real-time biometrics and objective measurements of physiology, ... music at scale in large populations. It is ... technologists and clinicians perform rigorous studies and accelerate ...
(Date:3/10/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ... biometric authentication company focused on the growing mobile ... has been named the "Number One Best Tech ... Rethink Modern ( http://www.rethinkmodern.com/ ) is a web ... and lifestyle that have a unique function or design.  ...
(Date:3/2/2015)... SAN JOSE, Calif. , March 2, 2015 ... ), the leading developer of human interface solutions, ... ID technology that is designed to enable rapid ... Synaptics Natural ID™ module for gaming is a ... and ODMs the ability to quickly integrate fingerprint ...
Breaking Biology News(10 mins):Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3
(Date:3/30/2015)... , March 30, 2015 CASI Pharmaceuticals, Inc. ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a commercial focus on China ... Drug Administration (CFDA) has approved the Company,s application to ... clear cell carcinoma (OCCC) patients for its proprietary drug ...
(Date:3/30/2015)... GERMANTOWN, Md. , March 30, 2015  /PRNewswire/ ... a leader in synthetic biology, and Merck Serono, ... Germany , today announced an exclusive ... commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. ... to develop innovative therapies that modulate the immune ...
(Date:3/30/2015)... Washington, USA (PRWEB) March 29, 2015 ... and the United States and plenary talks by four ... SPIE Optics + Optoelectronics next month in ... technical presentations in 17 conferences alongside a two-day exhibition. ... and photonics , the event will run 13-16 April ...
(Date:3/30/2015)... 2015  Naldemedine, an investigational peripherally acting mu-opioid ... Co., Ltd., met its primary and secondary endpoints ... the treatment of opioid-induced constipation (OIC) in adult ... Study results showed that naldemedine (0.2 mg tablet ... of spontaneous bowel movement (SBM) compared with placebo ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3
Cached News: